What is the Impact Factor of Blood and Lymphatic Cancer-Targets and Therapy?

According to the latest Clarivate Journal Citation Reports (JCR), the Journal Impact Factor of Blood and Lymphatic Cancer-Targets and Therapy is 3.20, ranking in quartile Q2 of Web of Science (ESCI).

Is Blood and Lymphatic Cancer-Targets and Therapy indexed in Web of Science or Scopus?

Yes, Blood and Lymphatic Cancer-Targets and Therapy is indexed in Web of Science (ESCI, Q2 quartile). Furthermore, in Scopus (SCImago), it holds an SJR rating of N/A (Q2) and an H-index of N/A.

Who publishes Blood and Lymphatic Cancer-Targets and Therapy and what is the Article Processing Charge (APC)?

Blood and Lymphatic Cancer-Targets and Therapy is published by Dove Medical Press. For exact article processing charges and subscription guidelines, consult the official editorial guidelines.

WoS ESCI Q2Hybrid

Blood and Lymphatic Cancer-Targets and Therapy

Identifier (ISSN):1179-9889(Print)

•

Publisher:Dove Medical Press

Clarivate JCR Index Advisory: Active (ESCI)

Official Website Submission Portal Compare

Clarivate IF (2026)

3.2↓ -1.7

Journal Impact Factor

IF Trend↓

WoS Quartile

WoS ESCIJCR Quartile

Clarivate WoS JCR

WoS Categories↓

JCR Release Date: 2026-06-17

Impact Factor Trend (2023–2026)

Clarivate IF trend for Blood and Lymphatic Cancer-Targets and Therapy

WoS Q2

Annual Impact Factor Metric

Current (2026):3.2

Scopus SJR & Rank

N/A

SCImago Journal Rank citation prestige weighting

Scopus / Elsevier Data

H-Index (Hirsch Index)

N/A

papers with at least that number of citations each

WoS: ESCIQ2

Self-Citation Rate0%

Safe Level (< 15%)Warning Level (> 20%)

Self-citation below 15% indicates strong scholarly independence.

Volume & Open AccessHybrid

6articles/year

96.67% Gold OA•33.33% Original Research

Aims & Scope

Blood and Lymphatic Cancer: Targets and Therapy is an international, peer reviewed, open access journal focusing on blood and lymphatic cancer research, identification of therapeutic targets, and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival, and quality of life for the cancer patient. Specific topics covered in the journal include: Epidemiology, detection and screening Cellular research and biomarkers Identification of biotargets and agents with novel mechanisms of action Optimal clinical use of existing anticancer agents, including combination therapies Radiation, surgery, bone marrow transplantation Palliative care Patient adherence, quality of life, satisfaction Health economic evaluations.

Topics Covered (Recognized by AI)

MedicineBiologyInternal MedicineImmunologyGeneticsPathologyOncologyChemistryCancer ResearchBiochemistrySurgeryAntibodies & ImmunologyOncology & Cancer ResearchCell BiologyImmune SystemPhysics

Primary Research Areas

Oncology

Official Website NLM PubMed Catalog

0 calls

Special Issues

Calls for Papers

No active Calls for Papers found for this journal.

Expand

WoS Categories & Quartiles

Detailed JCR / JCI category rankings and quartile breakdown from Clarivate

Clarivate JCR & JCI

JCRESCI2026

ONCOLOGY

Rank161/333

IndexESCI

JCIESCI2026

ONCOLOGY

Rank181/333

IndexESCI

Category	Index	Rank	Quartile
ONCOLOGY	JCRESCI	161/333	Q2
ONCOLOGY	JCIESCI	181/333	Q3

Annual Historical Statistics & Publications

Track annual publication volume, total citations, and Impact Factor evolution

12 year

2026Latest

IF3.2

Articles / Year22

Total Citations3

2025

IF4.9

Articles / Year19

Total Citations17

2024

IF3.9

Articles / Year6

Total Citations31

2023

IF2.8

Articles / Year7

Total Citations78

2022

IF—

Articles / Year12

Total Citations288

Year	Impact Factor	Articles / Year	Total Citations
2026	3.2	22	3
2025	4.9	19	17
2024	3.9	6	31
2023	2.8	7	78
2022	—	12	288
2021	—	6	105
2020	—	2	41
2019	—	8	127
2018	—	6	202
2017	—	9	89
2016	—	5	68
2015	—	9	30

SCImago & Scopus Journal Intelligence

Not indexed in SCImago / Scopus database

This journal is currently not indexed in Scopus or is an academic publication indexed exclusively in Web of Science (WoS).

Academic Metric Intelligence

Journal Metrics & Citation Visualizations

Total Cites vs Self-Cites

Evaluation of scholarly independence and citation reach

Total citations steady growth

Self-citation: 0%

Citations per Document

Citation metric windows across 2, 3, and 4 years

Cites / Doc (4 years)Cites / Doc (3 years)Cites / Doc (2 years)

Chinese Academy of Sciences (CAS) Classification

Major / minor zone classification and CAS Early Warning List history

Major Category (Broad Field):

3区 (Zone 3)Medicine

Minor Category (Specific Field):

3区ONCOLOGY

CAS Early Warning List History:

Updated annually: 2020 – 2024

2020

Not warned

2021

Not warned

2022

Not warned

2023

Not warned

2024

Not warned

Academic Intelligence Overview & Context

ImpaQ Analysis

Blood and Lymphatic Cancer-Targets and Therapy (ISSN: 1179-9889) is a peer-reviewed international scholarly journal in the field of ONCOLOGY, published by Dove Medical Press in United Kingdom. The periodical holds a Journal Impact Factor (JIF) of 3.20, ranking in quartile Q2 of Web of Science (ESCI).

The journal enforces rigorous peer evaluation with an annual output of approximately 6 scientific articles. In terms of accessibility and author fees, it operates under the Hybrid model with APC fees are not specified. It serves as a benchmark publication platform for academics, researchers, and doctoral candidates seeking global research visibility.